Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
NEW YORK, March 16, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 27th Annual Healthcare Conference on March 21, 2017 at 3:55 p.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
